Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients

Surg Neurol. 1994 Dec;42(6):469-70. doi: 10.1016/0090-3019(94)90074-4.

Abstract

Pulmonary embolism (PE) is a severe complication in neurosurgery. The best treatment of PE is thrombolytic therapy, but the presence of either intracranial neoplasm or recent neurosurgical procedures is considered a major contraindication to this therapy. We have used urokinase thrombolytic therapy in nine of our patients with severe PE that occurred from 7 to 34 days after a neurosurgical operation. All patients survived. No intracranial hemorrhage occurred. We also advocate thrombolytic therapy for severe PE in patients who were recently operated on by neurosurgical procedure.

MeSH terms

  • Adult
  • Aged
  • Craniotomy
  • Female
  • Humans
  • Laminectomy
  • Male
  • Middle Aged
  • Postoperative Complications / drug therapy*
  • Pulmonary Embolism / drug therapy*
  • Retrospective Studies
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / therapeutic use*
  • Ventriculoperitoneal Shunt

Substances

  • Urokinase-Type Plasminogen Activator